CY1107096T1 - Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης - Google Patents

Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης

Info

Publication number
CY1107096T1
CY1107096T1 CY20071101601T CY071101601T CY1107096T1 CY 1107096 T1 CY1107096 T1 CY 1107096T1 CY 20071101601 T CY20071101601 T CY 20071101601T CY 071101601 T CY071101601 T CY 071101601T CY 1107096 T1 CY1107096 T1 CY 1107096T1
Authority
CY
Cyprus
Prior art keywords
paliperidone
methods
plasma concentration
detection
peak plasma
Prior art date
Application number
CY20071101601T
Other languages
English (en)
Inventor
Noymi V Yam
Iran Reyes
Nipun Davar
Atul D Ayer
Julie Lee
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of CY1107096T1 publication Critical patent/CY1107096T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Προβλέπονται φαρμακοτεχνικές μορφές και μέθοδοι για παροχή ανοδικού κατ’ ουσία ρυθμού αποδέσμευσης παλιπεριδόνης. Οι φαρμακοτεχνικές μορφές παρατεταμένης αποδέσμευσης όταν χορηγούνται εφάπαξ ημερησίως, προσφέρουν θεραπευτικά αποτελεσματικές, μέσης σταθερής κατάστασης συγκεντρώσεις παλιπεριδόνης στοπλάσμα. Το σχήμα των εφάπαξ ημερησίων δόσεων έχει ως αποτέλεσμα να προκύπτει μια μόνο μέγιστη συγκέντρωση παλιπεριδόνης στο πλάσμα κατά την περίοδο του 24ώρου. Επιπλέον, η μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα, επέρχεται σε χρόνο μετά τη χορήγηση της δόσης και εμφανίζεται σε μικρότερο βαθμό σε σχέση με τη μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα που επέρχεται μετά τη χορήγηση παλιπεριδόνης σε φαρμακοτεχνική μορφή άμεσης αποδέσμευσης.
CY20071101601T 2002-07-29 2007-12-18 Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης CY1107096T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26
EP03771910A EP1539115B1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (1)

Publication Number Publication Date
CY1107096T1 true CY1107096T1 (el) 2012-10-24

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101601T CY1107096T1 (el) 2002-07-29 2007-12-18 Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης

Country Status (29)

Country Link
US (1) US20040092534A1 (el)
EP (1) EP1539115B1 (el)
JP (1) JP4500679B2 (el)
KR (1) KR100699516B1 (el)
CN (1) CN1684670A (el)
AR (1) AR040721A1 (el)
AT (1) ATE373472T1 (el)
AU (1) AU2003256844A1 (el)
BR (1) BR0313139A (el)
CA (1) CA2494234C (el)
CO (1) CO5580742A2 (el)
CY (1) CY1107096T1 (el)
DE (1) DE60316454T2 (el)
DK (1) DK1539115T3 (el)
ES (1) ES2293039T3 (el)
HK (1) HK1072559A1 (el)
HR (1) HRP20050077B1 (el)
IL (1) IL166489A (el)
MX (1) MXPA05001191A (el)
MY (1) MY137049A (el)
NO (1) NO324821B1 (el)
NZ (1) NZ570198A (el)
PE (1) PE20040132A1 (el)
PL (1) PL210119B1 (el)
PT (1) PT1539115E (el)
RU (1) RU2321391C2 (el)
TW (1) TWI363637B (el)
WO (1) WO2004010981A1 (el)
ZA (1) ZA200501641B (el)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MX2007001563A (es) * 2004-08-04 2008-03-05 Johnson & Johnson Composicion para liberacion sostenida de farmaco que demuestra un patron de liberacion ascendente del orden cero, metodos para la elaboracion de dicha composicion.
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007081736A1 (en) * 2006-01-06 2007-07-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
PL3095447T3 (pl) 2006-02-03 2022-02-14 Opko Renal, Llc Leczenie niedoboru lub deficytu witaminy d 25-hydroksywitaminą d2 i 25- hydroksywitaminą d3
US20070232624A1 (en) 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
ES2497494T3 (es) 2006-06-21 2014-09-23 Opko Renal, Llc Método de tratamiento y prevención del hiperparatiroidismo secundario
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
KR101540369B1 (ko) 2007-04-25 2015-07-29 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
JP5444212B2 (ja) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
ES2374200T3 (es) * 2007-08-21 2012-02-14 Teva Pharmaceutical Industries Ltd. Formulación de liberación prolongada de paliperidona.
RU2470641C2 (ru) 2007-09-25 2012-12-27 Тева Фармасьютикал Индастриес Лтд. Стабильные составы иматиниба
CN105560176A (zh) 2007-12-19 2016-05-11 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
US20090247553A1 (en) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
EP2326312A1 (en) * 2008-07-25 2011-06-01 KRKA, D.D., Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
WO2010039722A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
WO2011045774A2 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
EP2547206B1 (en) * 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
WO2012014052A2 (en) 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
MX2021014508A (es) 2014-04-04 2023-05-18 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
PT3838274T (pt) 2016-01-26 2023-12-18 Intra Cellular Therapies Inc Derivado de pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalina para utilização no tratamento de distúrbios do snc
CN113754661A (zh) 2016-03-25 2021-12-07 细胞内治疗公司 有机化合物
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
US20190105277A1 (en) 2016-04-05 2019-04-11 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3544593A4 (en) * 2016-11-23 2020-11-25 Children's Hospital Medical Center PALIPERIDONE FOR THE TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISTIC SPECTRUM DISORDER
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
AU2018307479B2 (en) 2017-07-26 2024-06-20 Intra-Cellular Therapies, Inc. Organic compounds
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
BR112020019119A2 (pt) 2018-03-23 2021-01-12 Intra-Cellular Therapies, Inc. Compostos orgânicos
US20210009592A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
EP3843739A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
DE69435104D1 (de) * 1993-09-28 2008-07-31 Scherer Gmbh R P Herstellung von Weichgelatinekapseln
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ATE234602T1 (de) * 1996-08-16 2003-04-15 Alza Corp Verabreichungsform zur abgabe von steigenden wirkstoffdosen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2229783T3 (es) * 1998-06-03 2005-04-16 Alza Corporation Dispositivos para proporcionar una terapia faramaceutica prolongada.
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
WO2000025790A1 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of antidepressants
EP1140012B1 (en) * 1998-12-17 2004-03-03 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
AU776645B2 (en) * 1999-03-31 2004-09-16 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
NO20050956L (no) 2005-04-27
ZA200501641B (en) 2005-08-31
JP4500679B2 (ja) 2010-07-14
ES2293039T3 (es) 2008-03-16
KR20050044895A (ko) 2005-05-13
DK1539115T3 (da) 2008-01-28
HK1072559A1 (en) 2005-09-02
MXPA05001191A (es) 2005-09-12
DE60316454D1 (de) 2007-10-31
WO2004010981A1 (en) 2004-02-05
US20040092534A1 (en) 2004-05-13
PE20040132A1 (es) 2004-03-06
AU2003256844A1 (en) 2004-02-16
MY137049A (en) 2008-12-31
EP1539115A1 (en) 2005-06-15
RU2005102105A (ru) 2005-08-10
PT1539115E (pt) 2008-01-14
PL210119B1 (pl) 2011-12-30
CA2494234C (en) 2009-10-27
HRP20050077B1 (hr) 2013-11-22
NZ570198A (en) 2010-01-29
IL166489A0 (en) 2006-01-15
HRP20050077A2 (en) 2005-12-31
BR0313139A (pt) 2005-07-05
CO5580742A2 (es) 2005-11-30
KR100699516B1 (ko) 2007-03-26
DE60316454T2 (de) 2008-06-26
EP1539115B1 (en) 2007-09-19
IL166489A (en) 2014-01-30
AR040721A1 (es) 2005-04-20
CA2494234A1 (en) 2004-02-05
PL376258A1 (en) 2005-12-27
CN1684670A (zh) 2005-10-19
TWI363637B (en) 2012-05-11
JP2005535682A (ja) 2005-11-24
ATE373472T1 (de) 2007-10-15
RU2321391C2 (ru) 2008-04-10
NO324821B1 (no) 2007-12-10
TW200418524A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
CY1107096T1 (el) Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
CY1106137T1 (el) Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
ATE541562T1 (de) Ibuprofen-suspension
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CY1110184T1 (el) Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας
EA200300110A1 (ru) Композиция элетриптана в виде частиц
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
EA200701409A1 (ru) Новая композиция
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering